Sema Mandal

Sema Mandal

Auto-generated profile, based on publicly available information

Sema Mandal

UK Health Security Agency London UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in The Lancet Child & Adolescent Health
Verified
Journal Article
Open access
SMSema Mandal
Sema Mandal
RSRuth Simmons
Ruth Simmons
GIGeorgina Ireland
Georgina Ireland
ACAndre Charlett
Andre Charlett
MDMonica Desai
Monica Desai
CWConall H Watson
Conall H Watson
An increase in acute severe hepatitis of unknown aetiology in previously healthy children in the UK in March, 2022, triggered global case-finding. We aimed to describe UK epidemiological investigations of cases and their possible causes. We actively surveilled unexplained paediatric acute hepatitis (transaminase >500 international units per litre) in children younger than 16 years presenting since Jan 1, 2022, through notifications from paediatricians, microbiologists, and paediatric liver units; we collected demographic, clinical, and exposure information. Then, we did a case-control study to investigate the association between adenoviraemia and other viruses and case-status using multivariable Firth penalised logistic regression. Cases aged 1-10 years and tested for adenovirus were included and compared with controls (ie, children admitted to hospital with an acute non-hepatitis illness who had residual blood samples collected between Jan 1 and May 28, 2022, and without known laboratory-confirmed diagnosis or previous adenovirus testing). Controls were frequency-matched on sex, age band, sample months, and nation or supra-region with randomised selection. We explored temporal associations between frequency of circulating viruses identified through routine laboratory pathogen surveillance and occurrence of cases by linear regression. SARS-CoV-2 seropositivity of cases was examined against residual serum from age-matched clinical comparison groups. Between Jan 1 and July 4, 2022, 274 cases were identified (median age 3 years [IQR 2-5]). 131 (48%) participants were male, 142 (52%) were female, and one (<1%) participant had sex data unknown. Jaundice (195 [83%] of 235) and gastrointestinal symptoms (202 [91%] of 222) were common. 15 (5%) children required liver transplantation and none died. Adenovirus was detected in 172 (68%) of 252 participants tested, regardless of sample type; 137 (63%) of 218 samples were positive for adenovirus in the blood. For cases that were successfully genotyped, 58 (81%) of 72 had Ad41F, and 57 were identified as positive via blood samples (six of these were among participants who had undergone a transplant). In the case-control analysis, adenoviraemia was associated with hepatitis case-status (adjusted OR 37·4 [95% CI 15·5-90·3]). Increases in the detection of adenovirus from faecal samples, but not other infectious agents, in routine laboratory pathogen surveillance correlated with hepatitis cases 4 weeks later, which independently suggested an association (β 0·06 [95% CI 0·02-0·11]). No association was identified for SARS-CoV-2 antibody seropositivity. We observed an association between adenovirus 41F viraemia and paediatric acute hepatitis. These results can inform diagnostic testing recommendations, clinical management, and exploratory in vitro or clinical studies of paediatric acute hepatitis of unknown aetiology. The role of potential co-factors, including other viruses and host susceptibility, requires further investigation. None.

9 January 2009 in Vaccine
Verified
Journal Article
Closed access
IGIsabelle Giraudon
Isabelle Giraudon
NPNadia Permalloo
Nadia Permalloo
GNGrainne Nixon
Grainne Nixon
ACAndre Charlett
Andre Charlett
SCSandra Cohuet
Sandra Cohuet
HMHelen Maguire
Helen Maguire

14 September 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
PDF file
KBKazim Beebeejaun
Kazim Beebeejaun
ZAZahin Amin‐Chowdhury
Zahin Amin‐Chowdhury
LLLouise Letley
Louise Letley
EKEdna Kara
Edna Kara
BMBeauty Mahange
Beauty Mahange
MEMichael Edelstein
Michael Edelstein
Around 200,000 people live with chronic hepatitis B in England. Despite national guidance on identification and management of cases and their close contacts, testing rates of close contacts is as low as 43% in high prevalence areas of London. Our study aimed to determine whether a nurse‐led enhanced management and contact tracing of chronically infected individuals improved testing uptake, vaccination and onward referral of close contacts. The study was conducted across Greater Manchester and East of England regions between October 2015 and July 2017. All HBV chronically infected individuals registered with a GP and their close contacts were eligible for recruitment. The proportion of contacts who were tested, vaccinated and referred where appropriate were compared before and after the nurse‐led intervention. Baseline and outcome information was collected using questionnaires. The intervention improved case referral rates by an additional 14% (from 86% (88/102 cases) to 99.7%; 648/650 cases). The proportion of contacts tested increased from 34% to 72%‐94% with 18 new cases of HBV diagnosed. Amongst close contacts tested, vaccination rates of at least three doses increased from 77% (43/56) to 93% (452/491) during the study. Our study has shown that nurse‐led enhanced management greatly improves identification, testing and vaccination of close contacts. The identification of new acute and chronic cases is likely to make the intervention cost effective and local health commissioners should consider providing a nurse‐led service as part of hepatitis B care pathways.

14 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MBMarta Bertran
Marta Bertran
NANick Andrews
Nick Andrews
CDChloe Davison
Chloe Davison
BDBennet Dugbazah
Bennet Dugbazah
JBJacob Boateng
Jacob Boateng
JBJamie Lopez Bernal
Jamie Lopez Bernal
Background Like many other countries worldwide, the UK experienced a national outbreak of monkeypox disease in May 2022, with case numbers rising rapidly, mainly among gay, bisexual and other men who have sex with men (GBMSM). To control the outbreak, Modified Vaccinia Ankara–Bavaria Nordic (MVA-BN), an attenuated smallpox vaccine, was offered to high-risk GBMSM. We assessed the effectiveness of a single MVA-BN dose against monkeypox disease in high-risk GBMSM. Methods Monkeypox cases in England were sent questionnaires collecting information on demographics, vaccination history and symptoms. Returned questionnaires with a rash onset date (or alternative proxy) between July 04 and October 09, 2022 were included. Females, heterosexual men, and those with missing vaccination information were excluded. Vaccine effectiveness was calculated using the case-coverage method where vaccine coverage among cases is compared to coverage in the eligible population, estimated from doses given to GBMSM and the estimated size of high-risk GBMSM. Sensitivity analysis included +/-20% differences in estimated high-risk GBMSM population size. Findings Vaccine uptake among eligible GBMSM increased steadily from July 2022, reaching 47% by October 09, 2022. Of the 363 confirmed cases, 8 occurred ≥14 days after vaccination, 32 within 0-13 days after vaccination, and the rest were unvaccinated. The estimated vaccine effectiveness ≥14 days after a single dose was 78% (95% CI: 54%-89%), with a range of ±7% in sensitivity analyses. Vaccine effectiveness within 0–13-days after vaccination was -4% (95% CI: -50% to 29%). Interpretation A single MVA-BN dose was highly protective against monkeypox disease among high-risk GBMSM. Funding None Evidence before this study We searched PubMed using the terms ‘monkeypox’, ‘MVA’ and ‘vaccine’, with no time limit, and used the snowball process to identify additional relevant publications. We also searched websites of regulatory authorities (FDA, EMA) for any data used during the regulatory approval processes. We also scoped pre-print databases vaccine effectiveness studies during the current outbreak. Only publications related to the Modified Vaccinia Ankara – Bavaria Nordic (MVA-BN) vaccine were included. In the UK, MVA-BN was offered to high-risk GBMSM to control a national outbreak which began in May 2022. MVA-BN is now licensed against smallpox in the US, Europe and the UK, there are, however, limited data on vaccine effectiveness against monkeypox. Preclinical studies indicated two vaccine doses were immunogenic and generated antibody levels considered protective against smallpox. Vaccine-induced antibodies are also cross-protective against monkeypox virus in vitro and in animal models. A recent, as yet unpublished, Israeli study estimated 79% vaccine effectiveness after one dose in high-risk GBMSM, while a US study reported unvaccinated individuals to be 14 times more likely to develop monkeypox disease than vaccinated persons. Added value of this study Few countries have recommended or introduced large-scale vaccination against the current global outbreak of monkeypox disease among GBMSM in non-endemic countries. The offer of MVA-BN to high-risk GBMSM through sexual health clinics in England provided a unique opportunity to rapidly assess vaccine effectiveness after a single dose using the case-coverage method, which involves comparing vaccine coverage in cases to vaccine coverage in the eligible population. Our vaccine effectiveness estimate of 78% at least 14 days after one MVA-BN dose is consistent with Israeli estimates and provided additional evidence of a lack of protection during the first 13 days after vaccination. Implications of all the available evidence A single dose of MVA-BN is highly protective against monkeypox disease and provides a useful tool for outbreak control when rapid protection may be needed. Given the lack of effectiveness in the first 13 days after the first dose and a median incubation period of 8-9 days after exposure to the virus, vaccination is likely to be most effective when offered as pre-exposure rather than prophylaxis. Because of the high vaccine effectiveness after one MVA-BN dose, in outbreaks where number of at-risk individuals exceed vaccine supply of two-doses, there may be benefit in prioritising delivery of first doses at the expense of delaying the second dose.

26 September 2023 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DEDavid Etoori
David Etoori
MDMonica Desai
Monica Desai
SMSema Mandal
Sema Mandal
WRWilliam Rosenberg
William Rosenberg
CSCaroline Anne Sabin
Caroline Anne Sabin
With the advent of direct acting antivirals, the World Health Organisation proposed eliminating Hepatitis C as a public health threat by 2030. To achieve this, countries need to diagnose, engage in care and treat their undiagnosed populations. This will require sensitisation campaigns. However previous media campaigns have had mixed impact. We conducted a scoping review to identify and understand the impact of previous Hepatitis C media campaigns. These findings could inform the delivery of future campaigns. We searched five electronic databases for published literature on media campaigns conducted for Hepatitis C awareness, testing, and treatment in Organisation for Economic Co-operation and Development (OECD) countries since 2010. Two independent reviewers screened citations for inclusion. Additionally, we spoke to stakeholders in the Hepatitis C field in the UK and conducted a Google search to identify any unpublished literature. A quantitative synthesis was conducted to identify targeted populations, strategies and media used, aims and impact of the campaigns. A title and year of publication screening of 3815 citations resulted in 113 papers that had a full abstract screen. This left 50 full-text papers, 18 were included of which 9 (50%) were from Europe. 5 (27.8%) of campaigns targeted minority ethnicities, and 9 (50%) aimed to increase testing. A Google search identified 6 grey literature sources. Most campaigns were not evaluated for impact. Discussions with stakeholders identified several barriers to successful campaigns including lack of targeted messaging, stigmatising or accusatory messaging, and short-lived or intermittent campaign strategies. Future campaigns will likely need to be multifaceted and have multiple tailored interventions. Campaigns will need to be sizeable and robust, integrated into health systems and viewed as an ongoing service rather than one-offs.

26 September 2019 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
ANAntiopi Ntouva
Antiopi Ntouva
BSBharat Sibal
Bharat Sibal
KBKoye Balogun
Koye Balogun
SMSema Mandal
Sema Mandal
NHNick Harding
Nick Harding
Around 300 cases of hepatitis A are reported annually,4 with 3–4 local clusters reported to PHE each year.3 In 2017, there was a surge in the number of hepatitis A virus cases (942 cases) as a result of a large outbreak predominantly in men who have sex with men (MSM), and further transmission into the wider community.4